直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Firm
  • Offices
  • Careers
Finnegan
  • Articles & Books
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • IP Health Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
  • Unified Patent Court (UPC) Hub

Our Insights

IP Health Blog

Finnegan’s IP Health Blog provides news and information about notable IP issues relating to health and medicine, including pharmaceuticals, biologics, medical devices, digital health, fitness, wellness, and nutrition, as well as related FDA rulings and guidance.
Editors
Associate Editors
Contributors
About
Arpita Bhattacharyya, Ph.D.
Partner
Palo Alto, CA
+1 650 849 6650
Email
Paul W. Browning, Ph.D.
Partner
Washington, DC
+1 202 408 4134
Email
Justin_Hasford
Justin J. Hasford
Partner
Washington, DC
+1 202 408 4175
Email
Ryan_O'Quinn
Ryan P. O'Quinn, Ph.D.
Partner
Reston, VA
+1 571 203 2426
Email
Jeffrey_Smyth
Jeffrey D. Smyth
Partner
Palo Alto, CA
+1 650 849 6618
Email
Kelly_Horn
Kelly S. Horn
Associate
Washington, DC
+1 202 408 4313
Email
Jordan Fraboni
Associate
Palo Alto, CA
+1 650 849 6646
Email
Kathryn R. Judson
Associate
Atlanta, GA
+1 404 653 6466
Email
Megan_Meyers
Megan L. Meyers
Associate
Atlanta, GA
+1 404 653 6565
Email
Marcelo Barros
Associate
Palo Alto, CA
+1 650 849 6619
Email
Meredith_Boerschlein
Meredith H. Boerschlein
Associate
Washington, DC
+1 202 408 4454
Email
Emily_Gabranski
Emily R. Gabranski
Associate
Washington, DC
+1 202 408 4331
Email
Jordan M. Gringauz
Associate
Washington, DC
+1 202 408 4143
Email
Kenneth S. Guerra
Associate
Washington, DC
+1 202 408 4124
Email
Yoonhee Kim
Yoonhee Kim
Partner
Washington, DC
+1 202 408 4214
Email
Kassandra_Officer
Kassandra M. Officer
Partner
Washington, DC
+1 202 408 4270
Email
Jessica_Roberts
Jessica L. Roberts, Ph.D.
Associate
Washington, DC
+1 202 408 4323
Email
Sonja_Sahlsten
Sonja W. Sahlsten
Associate
Washington, DC
+1 202 408 4329
Email
Christopher W. Weber, Ph.D.
Associate
Washington, DC
+1 202 408 4432
Email
Jason Y. Zhang, M.D.
Associate
Palo Alto, CA
+1 650 849 6732
Email

About This Blog

Disclaimer

Never miss an insight.

Sign up

Recent Insights in IP Health Blog

to

IP Health Blog

Patenting Good Vibrations to Reduce Chronic Stress Patenting Good Vibrations to Reduce Chronic Stress

October 25, 2022

IP Health Blog

A Survey of Patents Filed on Methods and Products for Overcoming Jet Lag A Survey of Patents Filed on Methods and Products for Overcoming Jet Lag

September 12, 2022

IP Health Blog

FDA Draft Guidance on Evaluation of Therapeutic Equivalence FDA Draft Guidance on Evaluation of Therapeutic Equivalence

August 4, 2022

IP Health Blog

A Brief Summary of Patent Proceedings Involving Cannabis Patents A Brief Summary of Patent Proceedings Involving Cannabis Patents

June 23, 2022

IP Health Blog

Smart Baby Monitors May Be Considered Medical Devices by FDA Smart Baby Monitors May Be Considered Medical Devices by FDA

June 16, 2022

IP Health Blog

Final FDA Guidance on Safety Considerations for Medication Container Labels and Carton Labeling Final FDA Guidance on Safety Considerations for Medication Container Labels and Carton Labeling

June 10, 2022

IP Health Blog

Defendants Allowed to Hide the Ball on Their Combination of Prior Art References Defendants Allowed to Hide the Ball on Their Combination of Prior Art References

May 5, 2022

IP Health Blog

Considerations for Protecting Trade Secrets in FDA Correspondence Considerations for Protecting Trade Secrets in FDA Correspondence

April 12, 2022

IP Health Blog

ANDA Specification Controls Infringement Analysis, Not Expert Testimony ANDA Specification Controls Infringement Analysis, Not Expert Testimony

March 10, 2022

IP Health Blog

“Show More of You”: Amgen v. Sandoz, Battling it Out on Amgen’s Otezla® Drug “Show More of You”: Amgen v. Sandoz, Battling it Out on Amgen’s Otezla® Drug

January 18, 2022

IP Health Blog

Formulation and Administration Claims Asserted in Hatch-Waxman Pass Muster Formulation and Administration Claims Asserted in Hatch-Waxman Pass Muster

November 8, 2021

IP Health Blog

Federal Circuit Crystallizes BMS’ Apixaban District Court Win Federal Circuit Crystallizes BMS’ Apixaban District Court Win

September 27, 2021

IP Health Blog

Testing the Limits of Therasense: Patent Owner’s Decision Not to Appeal Obviousness Holding Created But-for Materiality and Knowledge of Withheld References Established Intent Testing the Limits of Therasense: Patent Owner’s Decision Not to Appeal Obviousness Holding Created But-for Materiality and Knowledge of Withheld References Established Intent

September 20, 2021

IP Health Blog

Update to the Purple Book in Recent COVID-19 Stimulus Bill and Implications for BPCIA Litigation Update to the Purple Book in Recent COVID-19 Stimulus Bill and Implications for BPCIA Litigation

December 23, 2020

IP Health Blog

FDA Final Guidance on Enhancing the Diversity of Clinical Trial Populations FDA Final Guidance on Enhancing the Diversity of Clinical Trial Populations

November 19, 2020

IP Health Blog

FDA Final Guidance on Amendments and Requests for Final Approval to Tentatively Approved ANDAs FDA Final Guidance on Amendments and Requests for Final Approval to Tentatively Approved ANDAs

November 3, 2020

IP Health Blog

FDA Draft Guidance on Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe FDA Draft Guidance on Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe

November 2, 2020

IP Health Blog

A Major Decision Evaluating the Effect of a Skinny Label in a Post-Launch, Non-Hatch Waxman Litigation, Jury Trial World A Major Decision Evaluating the Effect of a Skinny Label in a Post-Launch, Non-Hatch Waxman Litigation, Jury Trial World

October 13, 2020

IP Health Blog

Modernization of the Orange Book Modernization of the Orange Book

September 15, 2020

IP Health Blog

IPO Recommendations for Changes to the Orange Book Listing Form 3542 IPO Recommendations for Changes to the Orange Book Listing Form 3542

September 9, 2020

IP Health Blog

FDA Draft Guidance on Drug-Drug Interaction Assessment for Therapeutic Proteins FDA Draft Guidance on Drug-Drug Interaction Assessment for Therapeutic Proteins

August 21, 2020

IP Health Blog

The Interplay Between the FDA Regulatory Process for Medical Devices and Patent Law – Considerations for 510(k) Submission The Interplay Between the FDA Regulatory Process for Medical Devices and Patent Law – Considerations for 510(k) Submission

August 4, 2020

IP Health Blog

The Interplay Between the FDA Regulatory Process for Medical Devices and Patent Law – FDA Premarket Review of Medical Devices The Interplay Between the FDA Regulatory Process for Medical Devices and Patent Law – FDA Premarket Review of Medical Devices

July 28, 2020

IP Health Blog

Proposed Revisions to Form 3542 with Explanations Proposed Revisions to Form 3542 with Explanations

July 8, 2020

IP Health Blog

FDA Draft Guidance on the Orange Book - Questions and Answers FDA Draft Guidance on the Orange Book - Questions and Answers

June 8, 2020

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

The Finnegan UPC Hub is a one-stop shop for our insights related to the Unified Patent Court (UPC).

Finnegan
Click Here
  • Privacy
  • Disclaimer
  • EEO Statement

© 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP